麻豆传媒

Oncology/Hematology >

Hematology

News, opinions and meeting coverage in oncology/hematology.

Amyloidosis Treatments Miss the Heart of the Problem

Only modest improvement in end organ function

Bangladesh-Boston Collaborate on ASCT Center

Two dozen patients undergo successful stem cell transplant in Dhaka

Survival Boost With Liposomal Tx in Older AML Patients

Agent may also provide a bridge to successful transplant

Novel Sickle Cell Tx Shows Promise for Pain Crises

Monoclonal antibody tied to lower incidence of adverse events

Keeping Chemo Patients Away From Hospitals

Is 'Come Home' ready for prime time?

Former NCI Chief Niederhuber Shifts Gears

At age 78, still active in research and administration

CML Patients Still Benefit from Transplant

Also at SOHO: Ponatinib proves mettle in pretreated CML

MedPAC Looks at Ways to Adjust Misvalued Services

Commission debates grouping CPT codes into families

Hypomethylating Agents Useful in Low-Risk MDS

Objective responses in a majority of patients

Combo Boosts PFS in Tough-to-Treat Myeloma

Recurrent or relapsed disease susceptible to daratumumab-bortezomib-dexamethasone

Transplant Remains King for New Myeloma

Significant improvement in PFS versus systemic treatment

Opinion Makers: Jury Still Out on Gene-Guided DLBCL Therapy

Rationale for subtyping, but treatment data inconclusive

Medical Schools Boost Pain Management Education

In light of opioid epidemic, more schools focus on thoughtful prescribing

Is SAMHSA to Blame for a Broken Mental Health System?

Two members of Congress differ on how to fix a failing system

Teach Patients How to Communicate Symptoms Better

Patients should learn the eight characteristics of a symptom

Doctors Urged to Practice 'Conservative Diagnosis'

And sharing cell phone numbers is a good idea

Susan G. Komen Founder Steps Out of Spotlight

Nancy Brinker says she won't forget her "promise" to the breast cancer community

Viagra and Melanoma: Is There a Link?

Perry Wilson, MD, gives his take on Viagra, Cialis, and skin cancer

One Proteasome Inhibitor Tops Another in Relapsed Myeloma

Progression-free survival doubled with carfilzomib versus bortezomib

ASCO: Gazyva Doubles Average Remission Time in NHL

Obinutuzumab delays progression in rituximab-refractory indolent disease.

Antitibiotic-Chemo Combo Cuts Infection Risk in AML

Incidence of Streptococcus viridans more than halved with prophylaxis.

Injecting Opioid Tied to Blood Clotting Disorder

Are most clinicians aware of this side effect of oxymorphone drug abuse?

HDAC Inhibitor OK'd for Multiple Myeloma

Panobinostat targets histone deacetylases; first of its kind to win approval in myeloma.

Case Study: Fecal Transplant Clears K. Pneumoniae

Treatment of teenage girl suggests another use for fecal microbiota transplant.

ASCO: Myeloma Study Results Inconclusive

CHICAGO -- A trial comparing two immunomodulatory regimens for myeloma failed to demonstrate noninferiority for the newer drug.

ASCO: Combo Extends PFS in Relapsed Myeloma

CHICAGO -- Progression-free survival in relapsed/refractory myeloma increased significantly in patients treated with a three-drug regimen that included panobinostat versus a two-drug regimen, a randomized trial showed.

OncoBriefs: Myeloma Tx, In Situ Melanoma

Superficial melanoma conferred a risk of recurrent invasive melanoma similar to that of primary invasive melanoma, Australian investigators reported. The study is one of several oncology-related news items summarized in OncoBriefs.

OncoBlog: Driving the CAR to a Cancer Cure?

Is immunotherapy with chimeric antigen receptor (CAR)-directed T cells the "next big thing" in oncology? Presentations and discussion at a recent conference suggest the technology has considerable promise -- but will it qualify as a breakthrough? OncoBlog is a blog by the Medpage Today staff for readers with an interest in oncology. This post comes from Charles Bankhead.

Gene Therapy Works in SCID With No Risk of Leukemia

NEW ORLEANS -- Genetic therapy appeared to restore the immune system of patients with X-linked severe combined immunodeficiency (SCID), but without leading to leukemia as a side effect, researchers reported here.

Stem Cells Help ALD Kids Live Longer

AUSTIN, Texas -- Survival in children with cerebral adrenocerebral adrenoleukodystrophy (ALD) appeared to be improved with allogeneic hematopoietic cell transplants compared with untreated patients, a researcher said here.

Lab Notes: Meth May Worsen Fungal Infection

Mice injected with methamphetamine and exposed to Cryptococcus fungi showed more extensive and hard-to-eradicate infections. Also this week: an organic pesticide fights parasitic worms.

Sjogren's Carries Heavy Disease Burden

BIRMINGHAM, England -- Patients with primary Sjogren's syndrome are prone to develop serious complications over the long term, despite the presumption that this is a relatively benign autoimmune disease, a 25-year review found.

Fatal Reactions Prompt Omontys Recall

All lots of the new anemia drug peginesatide (Omontys) have been recalled because of severe hypersensitivity reactions -- some fatal -- observed after the drug was approved last March.

Infection High in Myeloma, with High Mortality

ATLANTA -- More than a fifth of patients with multiple myeloma died of infection within a year of diagnosis, Swedish investigators reported here.

Oral Azacitidine Safe, Effective in Low-Risk MDS

ATLANTA -- Oral azacitidine (Vidaza) given for up to 21 days per 4-week cycle for myelodysplastic syndrome appeared safe and effective in patients with lower-risk disease, a researcher said here.

Children OK with Long-Term Exjade

ATLANTA -- Children with thalassemia and treated with the anti-iron overload drug deferasirox (Exjade) appear to tolerate the treatment for at least as long as 3 years while serum iron levels fell, researchers said here.

Extended Apixaban Stops VTE Recurrence

ATLANTA -- Apixaban taken for an additional year after standard venous thromboembolism (VTE) treatment reduced recurrent events in a placebo-controlled trial, researchers said.

Polycythemia Vera Better with Low Hematocrit

ATLANTA -- Maintaining patients with polycythemia vera at hematocrit levels below 45% reduced thrombotic complications without increasing rates of other serious adverse events.

Melanoma Tx Ups Survival, but Very Pricey

LAS VEGAS -- The oral BRAF inhibitor vemurafenib (Zelboraf) increased survival in patients with metastatic melanoma, but the cost may not justify its use in a state Medicaid program, an analysis suggested.

Repeat CT Scans May Up Breast Ca Risk in Young Women

CHICAGO -- A female teenager who undergoes multiple chest or cardiac CT studies may see her 10-year risk for breast cancer double, researchers said here.

鈥�

13